Jul 13, 2024, 11:17
David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients
David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn:
“Great news, a new option in our 1st line strategy for NSCLC EGFRmut patients! To be discussed especially in our patients with brain metastases, ctDNA+ or high tumor load.”
Source: David Planchard/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 10, 2024, 02:33
Sep 10, 2024, 02:28
Sep 10, 2024, 02:24
Sep 10, 2024, 02:18
Sep 10, 2024, 02:13
Sep 10, 2024, 02:03
Sep 10, 2024, 02:00
Sep 10, 2024, 01:58
Sep 10, 2024, 01:44